Ischemic stroke

Qualifying pharmacological strategies for prevention

Peter L. Salgo, Gregory W. Albers, Louis R. Caplan, Philip B. Gorelick, Ralph L Sacco

Research output: Contribution to journalArticle

Abstract

According to the American Stroke Association, 600,000 Americans will experience a new or recurrent stroke in 2002, and the cost of stroke-related care and disability will accrue to $49 billion. Although therapy with recombinant tissue-type plasminogen activator (tPA) has proved effective in ischemic stroke, very few patients receive this intervention - in one recent study of ischemic stroke, less than 5% of patients were treated with tPA. "This, coupled with a lack of other options and high rates of mortality and long-term disability, make primary and secondary prevention of stroke all the more essential," observed Peter L. Salgo, MD, who is Medical Correspondent with WCBS-Television, New York; Clinical Professor of Medicine and Anesthesiology at Columbia University College of Physicians and Surgeons; and Associate Director of Surgical Intensive Care Units at New York-Presbyterian Hospital in New York, New York. A key to successful stroke prevention management, commented Dr. Salgo, is the ability "to qualify pharmacological strategies for primary and secondary stroke prevention. This Medical Crossfire among a panel of national experts will assist in meeting the challenges clinicians face in preventing stroke.".

Original languageEnglish
Pages (from-to)30-43
Number of pages14
JournalMedical Crossfire
Volume5
Issue number2
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Stroke
Pharmacology
Secondary Prevention
Anesthesiology
Plasminogen Activators
Clinical Medicine
Television
Tissue Plasminogen Activator
Primary Prevention
Critical Care
Intensive Care Units
Physicians
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Medicine(all)
  • Health Policy

Cite this

Salgo, P. L., Albers, G. W., Caplan, L. R., Gorelick, P. B., & Sacco, R. L. (2003). Ischemic stroke: Qualifying pharmacological strategies for prevention. Medical Crossfire, 5(2), 30-43.

Ischemic stroke : Qualifying pharmacological strategies for prevention. / Salgo, Peter L.; Albers, Gregory W.; Caplan, Louis R.; Gorelick, Philip B.; Sacco, Ralph L.

In: Medical Crossfire, Vol. 5, No. 2, 01.03.2003, p. 30-43.

Research output: Contribution to journalArticle

Salgo, PL, Albers, GW, Caplan, LR, Gorelick, PB & Sacco, RL 2003, 'Ischemic stroke: Qualifying pharmacological strategies for prevention', Medical Crossfire, vol. 5, no. 2, pp. 30-43.
Salgo PL, Albers GW, Caplan LR, Gorelick PB, Sacco RL. Ischemic stroke: Qualifying pharmacological strategies for prevention. Medical Crossfire. 2003 Mar 1;5(2):30-43.
Salgo, Peter L. ; Albers, Gregory W. ; Caplan, Louis R. ; Gorelick, Philip B. ; Sacco, Ralph L. / Ischemic stroke : Qualifying pharmacological strategies for prevention. In: Medical Crossfire. 2003 ; Vol. 5, No. 2. pp. 30-43.
@article{ec6979db5923454e91ee8089a8f7fd9f,
title = "Ischemic stroke: Qualifying pharmacological strategies for prevention",
abstract = "According to the American Stroke Association, 600,000 Americans will experience a new or recurrent stroke in 2002, and the cost of stroke-related care and disability will accrue to $49 billion. Although therapy with recombinant tissue-type plasminogen activator (tPA) has proved effective in ischemic stroke, very few patients receive this intervention - in one recent study of ischemic stroke, less than 5{\%} of patients were treated with tPA. {"}This, coupled with a lack of other options and high rates of mortality and long-term disability, make primary and secondary prevention of stroke all the more essential,{"} observed Peter L. Salgo, MD, who is Medical Correspondent with WCBS-Television, New York; Clinical Professor of Medicine and Anesthesiology at Columbia University College of Physicians and Surgeons; and Associate Director of Surgical Intensive Care Units at New York-Presbyterian Hospital in New York, New York. A key to successful stroke prevention management, commented Dr. Salgo, is the ability {"}to qualify pharmacological strategies for primary and secondary stroke prevention. This Medical Crossfire among a panel of national experts will assist in meeting the challenges clinicians face in preventing stroke.{"}.",
author = "Salgo, {Peter L.} and Albers, {Gregory W.} and Caplan, {Louis R.} and Gorelick, {Philip B.} and Sacco, {Ralph L}",
year = "2003",
month = "3",
day = "1",
language = "English",
volume = "5",
pages = "30--43",
journal = "Medical Crossfire",
issn = "1525-9404",
publisher = "Liberty Communication Network Inc",
number = "2",

}

TY - JOUR

T1 - Ischemic stroke

T2 - Qualifying pharmacological strategies for prevention

AU - Salgo, Peter L.

AU - Albers, Gregory W.

AU - Caplan, Louis R.

AU - Gorelick, Philip B.

AU - Sacco, Ralph L

PY - 2003/3/1

Y1 - 2003/3/1

N2 - According to the American Stroke Association, 600,000 Americans will experience a new or recurrent stroke in 2002, and the cost of stroke-related care and disability will accrue to $49 billion. Although therapy with recombinant tissue-type plasminogen activator (tPA) has proved effective in ischemic stroke, very few patients receive this intervention - in one recent study of ischemic stroke, less than 5% of patients were treated with tPA. "This, coupled with a lack of other options and high rates of mortality and long-term disability, make primary and secondary prevention of stroke all the more essential," observed Peter L. Salgo, MD, who is Medical Correspondent with WCBS-Television, New York; Clinical Professor of Medicine and Anesthesiology at Columbia University College of Physicians and Surgeons; and Associate Director of Surgical Intensive Care Units at New York-Presbyterian Hospital in New York, New York. A key to successful stroke prevention management, commented Dr. Salgo, is the ability "to qualify pharmacological strategies for primary and secondary stroke prevention. This Medical Crossfire among a panel of national experts will assist in meeting the challenges clinicians face in preventing stroke.".

AB - According to the American Stroke Association, 600,000 Americans will experience a new or recurrent stroke in 2002, and the cost of stroke-related care and disability will accrue to $49 billion. Although therapy with recombinant tissue-type plasminogen activator (tPA) has proved effective in ischemic stroke, very few patients receive this intervention - in one recent study of ischemic stroke, less than 5% of patients were treated with tPA. "This, coupled with a lack of other options and high rates of mortality and long-term disability, make primary and secondary prevention of stroke all the more essential," observed Peter L. Salgo, MD, who is Medical Correspondent with WCBS-Television, New York; Clinical Professor of Medicine and Anesthesiology at Columbia University College of Physicians and Surgeons; and Associate Director of Surgical Intensive Care Units at New York-Presbyterian Hospital in New York, New York. A key to successful stroke prevention management, commented Dr. Salgo, is the ability "to qualify pharmacological strategies for primary and secondary stroke prevention. This Medical Crossfire among a panel of national experts will assist in meeting the challenges clinicians face in preventing stroke.".

UR - http://www.scopus.com/inward/record.url?scp=0037347274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037347274&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 30

EP - 43

JO - Medical Crossfire

JF - Medical Crossfire

SN - 1525-9404

IS - 2

ER -